Phaseline

Targets › LRRK2

LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2): drug programs, companies and trials

4 programs from 4 companies in 6 trials: 5 Phase 2, 1 Phase 3; Neurology; next expected readout Mar 2027.

Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking. Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation. (UniProt, Q5S007)

Open in Phaseline: the race on LRRK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyRemternetug (LY3372993)
LRRK2 inhibitor
LRRK2Phase 3Alzheimer's Disease; Alzheimers DiseaseApr 2029
Denali TherapeuticsBIIB122
LRRK2 kinase inhibitor
LRRK2Phase 2Parkinson DiseaseMar 2027
Neuron23NEU-411
LRRK2 inhibitor
LRRK2Phase 2Parkinson DiseaseDec 2027
SyntaraPXS-4728A
LRRK2 inhibitor
LRRK2Phase 2REM Sleep Behavior Disorder–

Conditions

Parkinson Disease (2) Alzheimers Disease (2) REM Sleep Behavior Disorder (1) Alzheimer's Disease (1)

Modalities

small molecule (3), antibody (1)

Companies

Syntara (1) Neuron23 (1) Denali Therapeutics (1) Eli Lilly (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.